Psoriasis is a common inflammatory disorder of the skin that typically presents with red, scaly, pruritic plaques. According to the World Health Organization, psoriasis affects between 1.5 and 5 percent of the world’s population.1 In the United Stated, there are approximately 7.4 million psoriasis patients. Between 60 and 90 percent of psoriasis patients also have chronic pruritus which many describe as the most bothersome symptom of this disease.2 While there are therapies designed to manage the immune and inflammatory aspects of psoriasis, there are no approved therapies primarily targeted to address pruritus associated with this disease.
Menlo Therapeutics believe there is strong scientific rationale that serlopitant may be an effective therapy for pruritus associated with psoriasis. We plan to initiate a phase 2 clinical study in the United States to evaluate the safety and efficacy of serlopitant to reduce the pruritus associated with psoriasis.